Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 1/2019

11.10.2018 | Editorial Commentary

Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer

verfasst von: Hossein Jadvar

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

Theranostics is currently experiencing a renaissance since the early days of radioiodine use in thyroid diseases. While there have been prior clinical platforms for theranostics (e.g., lymphoma, neuroblastoma), the recent regulatory approval and reimbursement of paired agents for somatostatin receptor-targeted theranostics of neuroendocrine tumors has helped to enrich the field [1]. Exciting developments are currently underway in theranostics of metastatic castrate-resistant prostate cancer (mCRPC), with prostate-specific membrane antigen (PSMA) as the biological target. Despite some limitations with nonspecificity, small molecule inhibitors binding to the external moiety of PSMA and radiolabeled with 68Ga- (e.g. PSMA-11, PSMA-617, PSMA I&T) or 18F- (e.g. DCFPyL, PSMA-1007) have demonstrated excellent diagnostic imaging performance and competitive advantage over other non-PSMA based radiotracers [2]. When radiolabeled with β-emitters (e.g., 177Lu, 131I) or α-emitters (e.g., 225Ac, 213Bi), particular PSMA-based agents can also be used for targeted radiotherapy of the same metastatic lesions that are identified by the imaging companion agent realizing the bidirectional “see & treat” concept [39]. …
Literatur
1.
Zurück zum Zitat Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in cancer diagnosis and management. Radiology. 2018;286:388–400.CrossRef Jadvar H, Chen X, Cai W, Mahmood U. Radiotheranostics in cancer diagnosis and management. Radiology. 2018;286:388–400.CrossRef
2.
Zurück zum Zitat Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging. 2018;17:1536012118776068.CrossRef Rahbar K, Afshar-Oromieh A, Jadvar H, Ahmadzadehfar H. PSMA theranostics: current status and future directions. Mol Imaging. 2018;17:1536012118776068.CrossRef
3.
Zurück zum Zitat Kulkarni HR, Singh A, Langbein T, et al. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol. 2018;20180308:1. Kulkarni HR, Singh A, Langbein T, et al. Theranostics of prostate cancer: from molecular imaging to precision molecular radiotherapy targeting the prostate specific membrane antigen. Br J Radiol. 2018;20180308:1.
4.
Zurück zum Zitat Sartor O, Sharma D. Radium and other alpha emitters in prostate cancer. Transl Androl Urol. 2018;7:436–44.CrossRef Sartor O, Sharma D. Radium and other alpha emitters in prostate cancer. Transl Androl Urol. 2018;7:436–44.CrossRef
5.
Zurück zum Zitat Poty S, Francesconi LC, McDevitt MR, et al. α-emitters for radiochemistry: from basic radiochemistry to clinical studies—part 1. J Nucl Med. 2018;59:878–84.CrossRef Poty S, Francesconi LC, McDevitt MR, et al. α-emitters for radiochemistry: from basic radiochemistry to clinical studies—part 1. J Nucl Med. 2018;59:878–84.CrossRef
6.
Zurück zum Zitat Poty S, Francesconi LC. McDevitt MR, et al. α-emitters for radiochemistry: from basic radiochemistry to clinical studies—part 2. J Nucl Med. 2018;59:1020–7.CrossRef Poty S, Francesconi LC. McDevitt MR, et al. α-emitters for radiochemistry: from basic radiochemistry to clinical studies—part 2. J Nucl Med. 2018;59:1020–7.CrossRef
7.
Zurück zum Zitat Morgenstem A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm 2018. [Epub ahead of print]. Morgenstem A, Apostolidis C, Kratochwil C, et al. An overview of targeted alpha therapy with 225Actinium and 213Bismuth. Curr Radiopharm 2018. [Epub ahead of print].
8.
Zurück zum Zitat Kiess AP, Minn I, Vaidyanathan G, et al. (2S)-2-(3-(1-carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569–75.CrossRef Kiess AP, Minn I, Vaidyanathan G, et al. (2S)-2-(3-(1-carboxy-5-(4-211At-Astatobenzamido)Pentyl)Ureido)-Pentanedioic acid for PSMA-targeted α-particle radiopharmaceutical therapy. J Nucl Med. 2016;57:1569–75.CrossRef
9.
Zurück zum Zitat Bandekar A, Zhu C, Jindal R, et al. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α–particle therapy of cancer. J Nucl Med. 2014;55:107–14.CrossRef Bandekar A, Zhu C, Jindal R, et al. Anti-prostate-specific membrane antigen liposomes loaded with 225Ac for potential targeted antivascular α–particle therapy of cancer. J Nucl Med. 2014;55:107–14.CrossRef
10.
Zurück zum Zitat Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.CrossRef Rahbar K, Ahmadzadehfar H, Kratochwil C, et al. German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients. J Nucl Med. 2017;58:85–90.CrossRef
11.
Zurück zum Zitat McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody [213Bi] J591 for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–100.PubMed McDevitt MR, Barendswaard E, Ma D, et al. An alpha-particle emitting antibody [213Bi] J591 for radioimmunotherapy of prostate cancer. Cancer Res. 2000;60:6095–100.PubMed
12.
Zurück zum Zitat Sathekge M, Knoesen O. Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100.CrossRef Sathekge M, Knoesen O. Meckel M, et al. 213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44:1099–100.CrossRef
13.
Zurück zum Zitat Kratochwil C, Schmidt K, Afshar-Oromieh A, et al. Targeted alpha-therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;2018(45):31–7.CrossRef Kratochwil C, Schmidt K, Afshar-Oromieh A, et al. Targeted alpha-therapy of mCRPC: dosimetry estimate of 213Bismuth-PSMA-617. Eur J Nucl Med Mol Imaging. 2018;2018(45):31–7.CrossRef
14.
Zurück zum Zitat Kratochwil C, Brucherseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.CrossRef Kratochwil C, Brucherseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. J Nucl Med. 2018;59:795–802.CrossRef
15.
Zurück zum Zitat Kratochwil C, Bruchertseifer F. Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.CrossRef Kratochwil C, Bruchertseifer F. Giesel FL, et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. J Nucl Med. 2016;57:1941–4.CrossRef
16.
Zurück zum Zitat Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31.CrossRef Kratochwil C, Bruchertseifer F, Rathke H, et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. J Nucl Med. 2017;58:1624–31.CrossRef
17.
Zurück zum Zitat Sathekge M, Bruchestseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naïve patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 2018. Sathekge M, Bruchestseifer F, Knoesen O, et al. 225Ac-PSMA-617 in chemotherapy-naïve patients with advanced prostate cancer: a pilot study. Eur J Nucl Med Mol Imaging 2018.
18.
Zurück zum Zitat Rathke H, Kratochwil C, Hohenbeger R, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging 2018. [Epub ahead of print]. Rathke H, Kratochwil C, Hohenbeger R, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. Eur J Nucl Med Mol Imaging 2018. [Epub ahead of print].
19.
Zurück zum Zitat Baum RP, Langbein T, Singh A, et al. Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept. Nucl Med Mol Imaging. 2018;52:80–1.CrossRef Baum RP, Langbein T, Singh A, et al. Injection of botulinum toxin for preventing salivary gland toxicity after PSMA radioligand therapy: an empirical proof of a promising concept. Nucl Med Mol Imaging. 2018;52:80–1.CrossRef
Metadaten
Titel
Value proposition of PSMA-targeted α–particle radioligand therapy in metastatic prostate cancer
verfasst von
Hossein Jadvar
Publikationsdatum
11.10.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 1/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4191-0

Weitere Artikel der Ausgabe 1/2019

European Journal of Nuclear Medicine and Molecular Imaging 1/2019 Zur Ausgabe